

SEQ ID NO: 3 refers to the amino acid sequence for salivaricin B including part of the leader peptide;

SEQ ID NO: 4 refers to the nucleotide sequence for salivaricin A2;

SEQ ID NO: 5 refers to the amino acid sequence for salivaricin A2 inclusive of the leader peptide;

SEQ ID NO: 6 refers to the amino acid sequence corresponding to the probe sequence.

SEQ ID NO: 7 refers to the nucleotide sequence corresponding to the probe sequence.--

Immediately after page 17 and before the first page of claims (page 18), if appropriate, please insert the enclosed pages identified as --Sequence Listing--. Please renumber the pages accordingly.

REMARKS

It is respectfully asserted that the sequence disclosure contained in the application now fully complies with the requirements set forth in 37 C.F.R. § 1.821 to § 1.825. Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

A copy of the Notice to Comply, a paper-copy of the Sequence Listing, and a computer readable form (floppy disk) of the Sequence Listing are enclosed. It is respectfully submitted that the Sequence Listing conforms to the requirements of 37 C.F.R. §1.823(b). The Statements required by 37 C.F.R §1.821(f) and (g) are set forth below.

Pursuant to 37 C.F.R. §1.821 (g), the undersigned attorney of record hereby states that this submission, filed in accordance with 37 C.F.R. §1.821 (g), does not contain new matter.

Pursuant to 37 C.F.R. §1.821 (f), the undersigned attorney hereby states that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821 (c) and (e), respectively, are the same.


These amendments are introduced merely to place the sequence listing in the application, (after the specification and before the claims) and to assign the proper SEQ ID Nos. to the sequences.

In view of the amendments, remarks and enclosures, the application complies with the requirements for computer readable disclosure of the biological sequences under 37 C.F.R. §§1.821-1.825. Reconsideration and withdrawal of the Notice to Comply is earnestly solicited.

If any additional fees are incurred for entry and consideration of this Amendment, the Examiner is authorized to charge any fees or credit any overpayment to Deposit Account No. 50-0320.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By:


Susan K. Lehnhardt
Reg. No. 33,943
(212) 588-0800

U.S. PATENT AND TRADEMARK OFFICE

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification:

New paragraph is added on Page 4, line 30 i.e. before the heading “Detailed Description of the Invention”:

SEQ ID NOs: are assigned as follows:

SEQ ID NO: 1 refers to the N-terminal sequence of salivaricin B;

SEQ ID NO: 2 refers to the nucleotide sequence for salivaricin B;

SEQ ID NO: 3 refers to the amino acid sequence for salivaricin B including part of the leader peptide;

SEQ ID NO: 4 refers to the nucleotide sequence for salivaricin A2;

SEQ ID NO: 5 refers to the amino acid sequence for salivaricin A2 inclusive of the leader peptide;

SEQ ID NO: 6 refers to the amino acid sequence corresponding to the probe sequence.

SEQ ID NO: 7 refers to the nucleotide sequence corresponding to the probe sequence.

CONFIDENTIAL